To include your compound in the COVID-19 Resource Center, submit it here.

Afrezza, partnered

What Sanofi must do for Afrezza to recoup $1.5B raised from MannKind's investors

Having signed on as the commercial partner for MannKind Corp.'s Afrezza inhaled insulin, Sanofi is clearly betting it can succeed where Exubera inhaled insulin from Pfizer Inc. and Nektar Therapeutics failed. To make the numbers add up for its investors, the biotech has to hope the pharma is right.

Under last week's deal, Sanofi will pay $150 million up front and take over responsibility for global commercial, regulatory and development activities for Afrezza,

Read the full 723 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE